Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
DARZALEX SC (Janssen-Cilag Pty Ltd)
Product name
DARZALEX SC
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 (255 working days)
Active ingredients
daratumumab
Registration type
EOI
Indication
DARZALEX SC (solution for injection) in combination with bortezomib, cyclophosphamide and dexamethasone, is now also indicated for the treatment of patients with light chain AL amyloidosis.